Janssen's Subcutaneous Daratumumab Quadruplet Regimen Approved in China for Newly Diagnosed Multiple Myeloma

Source: Global Times

On February 6, Johnson & Johnson's innovative therapeutic drug Darzalex Faspro®—daratumumab injection (subcutaneous injection)—was officially approved by the National Medical Products Administration for expanded indications in China. It will be used in combination with bortezomib, lenalidomide, and dexamethasone to treat newly diagnosed adult patients with multiple myeloma who are eligible for autologous stem cell transplantation. This means that patients at the newly diagnosed stage now have the opportunity to receive a four-drug combination regimen based on the subcutaneous injection formulation of daratumumab, providing a new treatment option that significantly improves prognosis.

Cherry Huang, President of Johnson & Johnson Innovative Medicine China, stated: "The treatment regimen approved this time brings significant clinical benefits to newly diagnosed multiple myeloma patients, reaffirming our commitment to bringing transformative solutions to more frontline treatment patients. At the same time, we also hope that the new treatment regimen based on the subcutaneous injection formulation of daratumumab will continue to promote improved treatment outcomes and establish a new standard of care."